Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SNOA

SNOA - Sonoma Pharmaceuticals Inc Stock Price, Fair Value and News

$3.37-0.02 (-0.59%)
Market Closed

49/100

SNOA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

49/100

SNOA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.37

Target 3M

$3.42

Target 6M

$3.4

SNOA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNOA Price Action

Last 7 days

3.1%

Last 30 days

-5.3%

Last 90 days

-14.7%

Trailing 12 Months

23.0%

SNOA RSI Chart

SNOA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SNOA Valuation

Market Cap

5.7M

Price/Earnings (Trailing)

-1.65

Price/Sales (Trailing)

0.34

EV/EBITDA

-0.82

Price/Free Cashflow

-2.44

SNOA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.37

Target 3M

$3.42

Target 6M

$3.4

SNOA Fundamentals

SNOA Revenue

Revenue (TTM)

16.9M

Rev. Growth (Yr)

56.58%

Rev. Growth (Qtr)

39.58%

SNOA Earnings

Earnings (TTM)

-3.5M

Earnings Growth (Yr)

12.46%

Earnings Growth (Qtr)

56.97%

SNOA Profitability

Operating Margin

40.43%

EBT Margin

-20.19%

Return on Equity

-91.87%

Return on Assets

-25.11%

Free Cashflow Yield

-40.91%

SNOA Investor Care

Shares Dilution (1Y)

27.02%

Diluted EPS (TTM)

-2.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202514.3M14.9M16.9M0
202412.7M12.7M13.5M14.0M
202313.3M12.7M12.1M12.3M
202212.6M12.9M12.5M12.6M
202118.6M16.5M14.5M12.5M
202017.9M19.2M20.2M20.8M
201919.0M19.1M18.9M18.0M
201816.7M17.2M17.8M18.2M
201712.8M14.0M15.5M17.0M
201612.8M11.8M10.5M11.4M
201513.9M14.1M14.9M14.2M
201413.7M13.7M12.9M12.8M
201315.5M14.8M14.3M14.1M
201212.7M13.9M14.7M15.5M
20119.8M10.4M11.6M12.1M
20100000
Get all data in R, Python etc through our Historical Stock Data APIs

About Sonoma Pharmaceuticals Inc

SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
 CEO
 WEBSITEsonomapharma.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES9

Sonoma Pharmaceuticals Inc Frequently Asked Questions

SNOA is the stock ticker symbol of Sonoma Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Sonoma Pharmaceuticals Inc is 5.73 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SNOA's fair value in chart for subscribers.

The fair value guage provides a quick view whether SNOA is over valued or under valued. Whether Sonoma Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Sonoma Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNOA.

As of Wed Jan 28 2026, SNOA's PE ratio (Price to Earnings) is -1.65 and Price to Sales (PS) ratio is 0.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNOA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Sonoma Pharmaceuticals Inc has provided -0.441 (multiply by 100 for percentage) rate of return.